Jazz Pharmaceuticals acquires Actio Biosciences for $820 million
Tweet Send to a Friend
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has completed its acquisition of privately-held Actio Biosciences, Inc. for $820 million upfront, making Actio ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




